About
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Key Metrics
as of Sep 2026Market Cap72 Cr
P/E64.70
Div Yield0.00 %
Book Value₹23.80
52w High₹43.80
52w Low₹27.00
Face Value₹10.00
Quarterly Results
Rs. Crores · hover row for definition| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 18.89 | 15.65 | 17.42 | 7.44 | 14.08 | 18.10 | 18.96 | 23.86 | 37.05 | 32.65 | 43.37 | 37.52 | 57.20 |
| Expenses | 16.40 | 13.17 | 14.24 | 7.13 | 25.12 | 22.23 | 19.27 | 24.65 | 33.63 | 33.29 | 39.20 | 37.26 | 51.39 |
| Operating Profit | 2.49 | 2.48 | 3.18 | 0.31 | -11.04 | -4.13 | -0.31 | -0.79 | 3.42 | -0.64 | 4.17 | 0.26 | 5.81 |
| OPM % | 13.18 | 15.85 | 18.25 | 4.17 | -78.41 | -22.82 | -1.64 | -3.31 | 9.23 | -1.96 | 9.61 | 0.69 | 10.16 |
| Other Income | 0.03 | 0.05 | 0.01 | 0.02 | 1.38 | 0.03 | 0.20 | 0.37 | 0.41 | 0.01 | 0.01 | 0.03 | 0.03 |
| Depreciation | 0.54 | 0.63 | 0.63 | 0.63 | 0.66 | 0.62 | 0.62 | 0.61 | 0.67 | 0.63 | 0.61 | 0.61 | 0.62 |
| Interest | 0.99 | 1.09 | 2.19 | 0.61 | 0.90 | 0.95 | 0.99 | 1.14 | 1.72 | 1.08 | 1.02 | 0.96 | 0.37 |
| Profit before tax | 0.99 | 0.81 | 0.37 | -0.91 | -11.22 | -5.67 | -1.72 | -2.17 | 1.44 | -2.34 | 2.55 | -1.28 | 4.85 |
| Tax % | 27.27 | -3.70 | -8.11 | -4.40 | -6.24 | 0.53 | 6.98 | -1.84 | -34.03 | -11.11 | 4.71 | -2.34 | 26.80 |
| Net Profit | 0.73 | 0.85 | 0.40 | -0.87 | -10.53 | -5.71 | -1.83 | -2.13 | 1.92 | -2.07 | 2.42 | -1.25 | 3.55 |
| EPS in Rs | 0.38 | 0.44 | 0.21 | -0.45 | -5.48 | -2.97 | -0.95 | -1.11 | 1.00 | -1.08 | 1.26 | -0.65 | 1.85 |
Profit & Loss
Annual · Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Sales | 59.40 | 75.00 | 150.59 | 212.29 | 191.10 | 243.48 | 0.00 |
| Expenses | 50.91 | 91.28 | 143.39 | 204.63 | 177.94 | 235.33 | 0.01 |
| Operating Profit | 8.49 | -16.28 | 7.20 | 7.66 | 13.16 | 8.15 | -0.01 |
| OPM % | 14.29 | -21.71 | 4.78 | 3.61 | 6.89 | 3.35 | — |
| Other Income | 0.10 | 1.99 | 0.46 | 0.12 | 0.29 | 0.39 | 0.00 |
| Interest | 4.89 | 3.98 | 4.78 | 3.38 | 2.09 | 2.67 | 0.00 |
| Depreciation | 2.41 | 2.50 | 2.52 | 2.37 | 2.02 | 1.81 | 0.00 |
| Profit before tax | 1.29 | -20.77 | 0.36 | 2.03 | 9.34 | 4.06 | -0.01 |
| Tax % | 13.18 | -2.79 | -183.33 | 38.42 | 28.91 | 56.16 | 0.00 |
| Net Profit | 1.11 | -20.19 | 1.03 | 1.25 | 6.64 | 1.78 | -0.01 |
| EPS in Rs | 0.58 | -10.52 | 0.54 | 0.65 | 3.46 | 0.93 | -0.11 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 | 13.89 | 0.00 | 0.00 |
Balance Sheet
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 19.21 | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 | 0.41 |
| Reserves | 26.40 | 5.43 | 25.51 | 24.46 | 24.00 | 17.40 | -0.01 |
| Borrowings | 45.33 | 40.05 | 44.30 | 31.09 | 26.51 | 12.48 | 0.00 |
| Other Liabilities | 33.84 | 39.84 | 37.84 | 51.08 | 73.59 | 69.64 | 0.00 |
| Total Liabilities | 124.78 | 94.54 | 116.87 | 115.85 | 133.32 | 108.74 | 0.40 |
| Fixed Assets | 24.24 | 25.46 | 26.92 | 26.65 | 21.38 | 19.67 | 0.00 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.19 | 0.21 | 0.18 | 0.13 | 0.14 | 0.12 | 0.00 |
| Other Assets | 100.35 | 68.87 | 89.77 | 89.07 | 111.80 | 88.95 | 0.40 |
| Total Assets | 124.78 | 94.54 | 116.87 | 115.85 | 133.32 | 108.74 | 0.40 |
Cash Flows
Annual · Rs. Crores — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -12.03 | 11.49 | -6.61 | -9.62 | 7.63 | 27.49 | 0.00 |
| Cash from Investing Activity | -1.11 | -3.18 | -2.22 | -6.69 | -3.68 | -7.81 | 0.00 |
| Cash from Financing Activity | 29.74 | -8.23 | 8.43 | 0.27 | 11.96 | 18.62 | 0.00 |
| Net Cash Flow | 16.60 | 0.08 | -0.40 | -16.03 | 15.91 | 38.30 | 0.00 |
| Free Cash Flow | -13.23 | 10.44 | -9.40 | -17.25 | 7.63 | 27.49 | 0.00 |
| CFO/OP % | -144.00 | -71.00 | -88.00 | -87.00 | 82.00 | 327.00 | 0.00 |
Ratios
Annual · Days / % — latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Debtor Days | 70.05 | 64.48 | 76.59 | 60.45 | 69.14 | 64.03 |
| Inventory Days | 606.03 | 259.67 | 158.26 | 97.79 | 109.19 | 73.12 |
| Days Payable | 239.52 | 174.65 | 103.37 | 73.90 | 161.20 | 114.08 |
| Cash Conversion Cycle | 436.56 | 149.50 | 131.48 | 84.34 | 17.13 | 23.07 |
| Working Capital Days | 88.98 | -37.28 | 28.48 | 20.63 | -19.46 | 14.41 |
| ROCE % | 8.49 | -27.95 | 6.65 | 8.69 | 23.13 | 34.08 |
Corporate Actions
6 records| Action | Ex Date | Record Date | Ratio | Amount (₹) | Notes |
|---|---|---|---|---|---|
| Rights | 23 Dec 2025 | 23 Dec 2025 | 13:12 | — | |
| Other | 23 Dec 2025 | 23 Dec 2025 | — | — | Right Issue of Equity Shares |
| Other | 17 Sep 2024 | — | — | — | Annual General Meeting |
| Other | 18 Sep 2023 | — | — | — | Annual General Meeting |
| Dividend | 19 Sep 2022 | 20 Sep 2022 | — | 1.00 | |
| Other | 22 Sep 2021 | — | — | — | Annual General Meeting |